Recently, we have demonstrated that nilotinib and KIRA8 exhibited anti-myeloma effects by targeting adaptive IRE1α signaling and modulating PERK signaling to induce T-UPR [10]. The gene discussed is EIF2AK3; the disease is plasma cell myeloma.